Ratio Therapeutics Inc, a Boston-based pharmaceutical company, announced on Tuesday that it has named Bill Cupelo as its new chief business officer and D. Scott Holbrook, MS, FSNMMI-TS as its new director.
Cupelo has more than 10 years of experience in sales with a focus on oncology and neurology. He has served as head of Sales at Invicro and vice president of Business Development and Strategic Accounts, and software product manager at Invicro.
Holbrook has 25 plus years of experience in the field of molecular imaging and therapeutics. Presently, he serves as the general manager and chief strategy officer at PharmaLogic.
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
Oncosure introduces Rapid Cancer Screening Test
Bayer and NextRNA collaborate on LncRNA-targeting therapeutics
GSK welcomes Delaware Supreme Court review of Zantac litigation
Fusion Antibodies expands collaboration with US National Cancer Institute
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
Astellas initiates Phase 3 study for fezolinetant in breast cancer patients
Cantargia updates clinical trial timelines for nadunolimab
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation